The IC50 values of the MCL1 inhibitor S63845 in CDS were comparable to those found in hematological malignancies, which are currently the focus of MCL1-targeted therapy, and significantly lower than those observed in almost all tested solid tumor cell lines45. The gene discussed is MCL1; the disease is hematologic disorder.